Roche Holding AG (ROG) and a group of outside investigators may share raw data from conflicting trials of Avastin to help determine whether the $7 billion-a-year treatment really helps patients with deadly brain cancer. The data is from two trials that both found the drug didn’t help patients with glioblastoma live longer, but differed on a more subjective measure: quality of life. In results published today in the New England Journal of Medicine, researchers who led a Roche-sponsored trial said Avastin improved or maintained quality of life and brain function.
Help employers find you! Check out all the jobs and post your resume.
